Eduard F Stange

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5494353/publications.pdf

Version: 2024-02-01

55 papers	2,570 citations	394421 19 h-index	206112 48 g-index
170 all docs	170 docs citations	170 times ranked	3446 citing authors

#	Article	IF	Citations
1	Mitochondria in Ulcerative Colitis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 352-353.	4.5	2
2	Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Zeitschrift Fur Gastroenterologie, 2021, 59, 1214-1223.	0.5	4
3	Twentyâ€five years of biologicals in IBD: WhatÂ´s all the hype about?. Journal of Internal Medicine, 2021, 290, 806-825.	6.0	15
4	Antagonism of Adherent Invasive E. coli LF82 With Human Î±-defensin 5 in the Follicle-associated Epithelium of Patients With Ileal Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2021, 27, 1116-1127.	1.9	4
5	Genetic risk factors predict disease progression in Crohnâ€™s disease patients of the Swiss inflammatory bowel disease cohort. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095925.	3.2	7
6	A new kid on the budesonide block. United European Gastroenterology Journal, 2020, 8, 1141-1142.	3.8	0
7	Fragmentation of Human Neutrophil Î±-Defensin 4 to Combat Multidrug Resistant Bacteria. Frontiers in Microbiology, 2020, 11, 1147.	3.5	11
8	Infodemiology of Crohnâ€™s disease and Ulcerative colitis using GoogleÂTrends â€“ an approach to investigate patient needs. Zeitschrift Fur Gastroenterologie, 2020, 58, 224-233.	0.5	6
9	Human Î²-Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis. Frontiers in Immunology, 2020, 11, 93.	4.8	52
10	An Update Review on the Paneth Cell as Key to Ileal Crohn's Disease. Frontiers in Immunology, 2020, 11, 646.	4.8	63
11	Microbiota and mucosal defense in IBD: an update. Expert Review of Gastroenterology and Hepatology, 2019, 13, 963-976.	3.0	98
12	Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide. Scientific Reports, 2019, 9, 3640.	3.3	20
13	Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohnâ€™s Disease. Inflammatory Intestinal Diseases, 2018, 3, 125-137.	1.9	6
14	Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. Inflammatory Intestinal Diseases, 2018, 3, 116-124.	1.9	20
15	Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Research, 2018, 7, 1207.	1.6	38
16	Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue. Scientific Reports, 2018, 8, 12886.	3.3	10
17	Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohnâ€™s Disease. Frontiers in Pharmacology, 2018, 9, 764.	3.5	0
18	Tu1787 - Human Beta-Defensin 2 Suppresses TNF-Alpha Secretion in Human and Mouse Dendritic Cells Mediated by Chemokine Receptor 2. Gastroenterology, 2018, 154, S-1019.	1.3	0

#	Article	IF	Citations
19	129 - Oral Delivery of Human Beta-Defensin 2 is Reversibly Increasing Microbiome Diversity and is Effective in the Treatment of Experimental Colitis. Gastroenterology, 2018, 154, S-34-S-35.	1.3	1
20	Î²-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor. Frontiers in Immunology, 2018, 9, 1735.	4.8	12
21	Gut microbiome, metabolic syndrome, and atherosclerosis. , 2018, , 1082-1085.		1
22	Improvement of a â€˜Leaky' Intestinal Barrier. Digestive Diseases, 2017, 35, 21-24.	1.9	11
23	Human Endogenous Retroviruses and Residues of Ancient Times - are Differentially Expressed in CrohÇ¹s Disease. Gastroenterology, 2017, 152, S985.	1.3	0
24	HDAC Mediated Regulation of the Antimicrobial HBD2 Differs between Intestinal Cell Lines and Cultured Tissue. Gastroenterology, 2017, 152, S999.	1.3	0
25	Recombinant Production of Human Beta-Defensin 2 (HBD2) as an Immune-Modulator: Improvement of Experimental Colitis. Gastroenterology, 2017, 152, S567.	1.3	0
26	In the Wnt of Paneth Cells: Immune-Epithelial Crosstalk in Small Intestinal Crohnâ€™s Disease. Frontiers in Immunology, 2017, 8, 1204.	4.8	20
27	Recent advances in understanding and managing Crohnâ€™s disease. F1000Research, 2016, 5, 2896.	1.6	14
28	Inflammatory Bowel Disease: Crohnâ€™s disease and ulcerative colitis. Deutsches Ärzteblatt International, 2016, 113, 72-82.	0.9	111
29	Antimicrobial Peptides in the Gut. , 2016, , 67-88.		1
30	In Reply. Deutsches Ärzteblatt International, 2016, 113, 462.	0.9	0
31	Management of Crohn's disease â€“ are guidelines transferred to clinical practice?. United European Gastroenterology Journal, 2015, 3, 371-380.	3.8	20
32	Sa1728 Chronic Alcohol Abuse Induces Paneth Cell Antimicrobial Expression in Gastric Mucosa - A Consequence of Wnt Signaling Aberrations?. Gastroenterology, 2015, 148, S-316.	1.3	0
33	Tu1835 Inflammatory Cells Enhance Defensin Expression via Peripheral Wnt Factors, Which Is Impaired in Ileal CD Patients. Gastroenterology, 2015, 148, S-915.	1.3	0
34	Medical Therapy of Perianal Crohn's Disease. Visceral Medicine, 2015, 31, 265-272.	1.3	8
35	Crohn's disease-derived monocytes fail to induce Paneth cell defensins. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14000-14005.	7.1	71
36	Association of FXR gene variants with cholelithiasis. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 68-79.	1.5	11

#	Article	IF	Citations
37	Intestinal barrier in inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 1165.	3.3	309
38	Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals. United European Gastroenterology Journal, 2014, 2, 216-225.	3.8	14
39	Gastrointestinal involvement in granulomatosis with polyangiitis and microscopic polyangiitis: histological features and outcome. International Journal of Rheumatic Diseases, 2014, 17, 412-419.	1.9	14
40	Therapeutic peptides in inflammatory bowel disease. Expert Opinion on Biological Therapy, 2014, 14, 455-466.	3.1	1
41	Synergistic Effects of Antimicrobial Peptides and Antibiotics against Clostridium difficile. Antimicrobial Agents and Chemotherapy, 2014, 58, 5719-5725.	3.2	80
42	TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease. American Journal of Physiology - Renal Physiology, 2014, 307, G487-G498.	3.4	41
43	The debated role for thiopurines in Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 172-174.	1.3	1
44	Human colonic mucus is a reservoir for antimicrobial peptides. Journal of Crohn's and Colitis, 2013, 7, e652-e664.	1.3	92
45	Antimicrobial Activity of High-Mobility-Group Box 2: a New Function to a Well-Known Protein. Antimicrobial Agents and Chemotherapy, 2013, 57, 4782-4793.	3.2	19
46	Gastric Antimicrobial Peptides Fail to Eradicate Helicobacter pylori Infection Due to Selective Induction and Resistance. PLoS ONE, 2013, 8, e73867.	2.5	33
47	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8772-8777.	7.1	183
48	Paneth's disease. Journal of Crohn's and Colitis, 2010, 4, 523-531.	1.3	115
49	In the case of nonresponse, what is the second-level treatment for induction of remission in CrohnÊ¼s disease?. Inflammatory Bowel Diseases, 2008, 14, S251-S252.	1.9	0
50	Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut, 2007, 56, 1240-1247.	12.1	138
51	The Case Against Using 5-Aminosalicyclates in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2005, 11, 613-615.	1.9	8
52	NF-Î²B- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells byEscherichia coliNissle 1917: a Novel Effect of a Probiotic Bacterium. Infection and Immunity, 2004, 72, 5750-5758.	2.2	437
53	Inducible and Constitutive Î²-Defensins Are Differentially Expressed in Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2003, 9, 215-223.	1.9	260
54	Crohn's disease. European Journal of Gastroenterology and Hepatology, 2003, 15, 627-634.	1.6	151

#	Article	IF	Citations
55	Step-Up or Top-Down, Combination with Immunosuppression or Not?. Frontiers of Gastrointestinal Research, 0, , 169-177.	0.1	0